BMY vs. SNY
BMY (Bristol-Myers Squibb Company) and SNY (Sanofi) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, BMY returned 2.16%/yr vs 4.59%/yr for SNY. Their 0.39 correlation means their historical movements had little consistent relationship.
Performance
BMY vs. SNY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BMY achieves a 25.17% return, which is significantly higher than SNY's -6.17% return. Over the past 10 years, BMY has underperformed SNY with an annualized return of 2.16%, while SNY has yielded a comparatively higher 4.59% annualized return.
BMY
- 1D
- 0.69%
- 1M
- 12.35%
- 6M
- 21.21%
- YTD
- 25.17%
- 1Y
- 54.75%
- 3Y*
- 6.92%
- 5Y*
- 3.38%
- 10Y*
- 2.16%
- ALL TIME*
- 9.43%
SNY
- 1D
- 0.44%
- 1M
- -0.19%
- 6M
- -3.34%
- YTD
- -6.17%
- 1Y
- -2.74%
- 3Y*
- -2.29%
- 5Y*
- 0.72%
- 10Y*
- 4.59%
- ALL TIME*
- 5.30%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $711.50M | $665.03M | $681.59M | |
SNY Sanofi | $172.97M | $151.05M | $146.29M |
BMY vs. SNY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 25.17% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
SNY Sanofi | -6.17% | 4.93% | 1.09% | 6.55% | 0.57% | 7.00% | 0.39% | 20.47% | 6.06% | 9.96% |
Correlation
The correlation between BMY and SNY is 0.46, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.46 |
Correlation (3Y) Balances recent behavior with more history. | 0.38 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.36 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.35 |
Correlation (All Time) Calculated using the full available price history since Jul 1, 2002 | 0.39 |
The correlation between BMY and SNY shifts across timeframes, from 0.35 (10 years) to 0.46 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
BMY:
$133.37B
SNY:
$103.44B
BMY:
$4.54
SNY:
€1.63
BMY:
14.37
SNY:
22.94
BMY:
0.82
SNY:
2.11
BMY:
2.71
SNY:
1.86
BMY:
5.99
SNY:
1.29
BMY:
$49.19B
SNY:
€48.92B
BMY:
$34.51B
SNY:
€35.72B
BMY:
$16.67B
SNY:
€12.41B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BMY vs. SNY — Risk / Return Rank
BMY
SNY
BMY vs. SNY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and Sanofi (SNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BMY | SNY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.16 | ||
| Sortino ratioReturn per unit of downside risk | +2.91 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.02 | +0.34 |
| Calmar ratioReturn relative to maximum drawdown | 4.66 | -0.02 | +4.68 |
| Martin ratioReturn relative to average drawdown | 11.09 | -0.04 | +11.13 |
Loading charts...
Drawdowns
BMY vs. SNY - Drawdown Comparison
The maximum BMY drawdown since its inception was -72.03%, which is greater than SNY's maximum drawdown of -46.46%. Use the drawdown chart below to compare losses from any high point for BMY and SNY.
Loading charts...
Drawdown Indicators
| BMY | SNY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.03% | -46.46% | -25.57% |
Max Drawdown (1Y)Largest decline over 1 year | -12.53% | -16.70% | +4.17% |
Max Drawdown (3Y)Largest decline over 3 years | -34.11% | -23.37% | -10.74% |
Max Drawdown (5Y)Largest decline over 5 years | -47.67% | -33.52% | -14.15% |
Max Drawdown (10Y)Largest decline over 10 years | -47.67% | -33.52% | -14.15% |
Current DrawdownCurrent decline from peak | -4.95% | -20.08% | +15.13% |
Average DrawdownAverage peak-to-trough decline | -22.36% | -12.24% | -10.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.25% | 9.59% | -4.34% |
Volatility
BMY vs. SNY - Volatility Comparison
Bristol-Myers Squibb Company (BMY) has a higher volatility of 9.10% compared to Sanofi (SNY) at 8.66%. This indicates that BMY's price experiences larger fluctuations and is considered to be riskier than SNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BMY | SNY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.10% | 8.66% | +0.44% |
Volatility (6M)Calculated over the trailing 6-month period | 19.64% | 17.58% | +2.06% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.86% | 26.74% | +1.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.49% | 25.17% | -0.68% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.46% | 23.49% | +1.97% |
Dividends
BMY vs. SNY - Dividend Comparison
BMY's dividend yield for the trailing twelve months is around 3.84%, less than SNY's 5.62% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 3.84% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
SNY Sanofi | 5.62% | 4.56% | 4.22% | 3.83% | 4.32% | 3.80% | 3.61% | 3.47% | 4.29% | 3.82% | 4.11% | 3.77% |
Financials
BMY vs. SNY - Financials Comparison
This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and Sanofi. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMY vs. SNY - Profitability Comparison
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Bristol-Myers Squibb Company reported a gross profit of 9.25B and revenue of 12.97B. Therefore, the gross margin over that period was 71.3%.
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Sanofi reported a gross profit of 9.28B and revenue of 12.30B. Therefore, the gross margin over that period was 75.5%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Bristol-Myers Squibb Company reported an operating income of 4.09B and revenue of 12.97B, resulting in an operating margin of 31.5%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Sanofi reported an operating income of 2.38B and revenue of 12.30B, resulting in an operating margin of 19.4%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Bristol-Myers Squibb Company reported a net income of 3.32B and revenue of 12.97B, resulting in a net margin of 25.6%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Sanofi reported a net income of 343.00M and revenue of 12.30B, resulting in a net margin of 2.8%.
Frequently Asked Questions
BMY and SNY have a correlation of 0.46, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BMY has higher volatility (9.10%) compared to SNY (8.66%). In terms of maximum drawdown, BMY dropped -72.03% vs SNY's -46.46%.
BMY currently has the higher Sharpe Ratio (2.14 vs -0.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BMY and SNY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer